Halozyme guides FY2023 revenue $815M-$845M, >20% growth; Non-GAAP EPS $2.50-$2.65

HALOZYME THERAPEUTICS, INC.

2022-FY EPS reported $1.44 revenue$660,116,000

FY2023 total revenue guidance $815M-$845M, >20% growth over expected 2022 record revenue >$655M.
Royalty revenue guided $445M-$455M (>20% growth); EBITDA $415M-$440M (>30% growth).
Non-GAAP diluted EPS guidance $2.50-$2.65; up to $150M share repurchases under $750M authorization.
Anticipates two ENHANZE SC launches (efgartigimod, atezolizumab) and four Phase 3 data readouts in 2023.
Completed Antares Pharma acquisition in 2022; expects continued strength in DARZALEX SC and Phesgo royalties.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

HALOZYME THERAPEUTICS, INC. reported 2023 results: revenue $815 million to $845 million, EPS $2.50 to $2.65. Guidance initiated.

Period: 2023
Revenue: $815 million to $845 million
EPS: $2.50 to $2.65
Guidance: initiated
Result: guidance update

Exact text from the filing

Halozyme expects total revenue of $815 million to $845 million

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

HALOZYME THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001159036-23-000004

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.